A study recently published in the “Scientific Reports” journal has found a potential link between Parkinson’s, strokes and the onset of heart disease. Researchers behind the study used a two-sample Mendelian randomization analysis to find links associations between cardiocerebrovascular illnesses and Parkinson’s disease (PD).
While some past studies have surmised that cardiocerebrovascular conditions and PD are related, those studies are relatively controversial.
The research team sought to investigate the potential effect of PD on cardiocerebrovascular disorders via the Mendelian randomization method. It leveraged data from 482,730 Europeans in the International PD Genomics Consortium’s publicly available genome-wide association study (GWAS) in order to find a potential connection between Parkinson’s disease and heart disease.
According to the study, 33,647 of the individuals had Parkinson’s disease while 449,056 acted as controls. The research team used five GWAS datasets to obtain single nucleotide polymorphisms (SNPs) outcome data.
The researchers studied cardiocerebrovascular diseases such as AF (atrial fibrillation), heart failure, coronary heart disease, myocardial infarction, ischemic stroke and large artery stroke. Consequently, the entire dataset was broken down into the following four categories: MI-linked SNP dataset, AF-linked SNP dataset, HF-linked dataset and CAD-related dataset.
Analysis of the data revealed that there was a significant association between Parkinson’s disease and 23 SNPs. Furthermore, a primary inverse variance-weighted risk analysis revealed that PD was associated with an increased likelihood of developing CAD, stroke and cardioembolic stroke.
Analysis methods such as weighted mean,Mendelian randomization-Egger, and simple and weighted modes yielded similar results.
Parkinson’s disease is associated with an increased CAD prevalence because it causes excessive deposition of Lewy bodies, which can result in abnormal function of residual noradrenergic endings, cardiac sympathetic denervation and reduced sympathetic innervation. PD patients have also reported exacerbated severe cardiac norepinephrine deficiencies due to classic PD symptoms such as dementia, tremors, bradykinesia, ankylosis and depression.
Because Parkinson’s disease impacts lipid metabolism, it can also affect the course of cardiovascular disease and elevate the risk of CAD with its progression. The disorder is also associated with a heightened risk of stroke, thanks to the accumulation of Lewy bodies, which can result in ischemic brain damage and neuronal damage through mitochondrial breakage, oxidative stress, autophagy and inflammation.
In summary, the study provides reliable evidence of a connection between Parkinson’s disease and an elevated risk of stroke, coronary artery disease, cardioembolic stroke and ischemic stroke. On the other hand, the research team did not find any connection between Parkinson’s disease and other cardiocerebrovascular disorders.
Hopefully, the success that enterprises such as Clene Inc. (NASDAQ: CLNN) register in developing effective treatments for Parkinson’s disease could help patients minimize the possible complications, such as heart disease, that arise when neurodegenerative ailments aren’t effectively managed.
NOTE TO INVESTORS: The latest news and updates relating to Clene Inc. (NASDAQ: CLNN) are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba…
VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment…
Earth Science Tech held its first annual meeting of stockholders, virtually, on August 31, 2026+…
As more Americans become underinsured or uninsured as a result of rising health insurance premiums and the several…
Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring…
BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them…